Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
75,602,672
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
80,197,042
-
Shares change
-
-2,241,574
-
Total reported value, excl. options
-
$1,608,751,464
-
Value change
-
-$51,643,382
-
Put/Call ratio
-
20%
-
Number of buys
-
67
-
Number of sells
-
-51
-
Price
-
$20.06
Significant Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL) as of Q3 2023
155 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80,197,042 shares
.
Largest 10 shareholders include Matrix Capital Management Company, LP (13,959,973 shares), FMR LLC (9,493,896 shares), EVENTIDE ASSET MANAGEMENT, LLC (7,814,039 shares), VANGUARD GROUP INC (5,236,663 shares), BlackRock Inc. (4,395,857 shares), Capital International Investors (3,127,758 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,715,599 shares), STATE STREET CORP (2,703,360 shares), CITADEL ADVISORS LLC (2,155,351 shares), and Avidity Partners Management LP (2,100,000 shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.